VBI Vaccines Inc Phase 1/2 Trial of VBI-2902a Data Update Call Transcript
Good morning. As we announce the initial positive Phase I data for the ongoing adaptive Phase I/II clinical study of VBI-2902a, our monovalent eVLP COVID-19 vaccine candidate.
Joining me on the call from VBI are Jeff Baxter, President and CEO; and David Anderson, Chief Scientific Officer.
We do have slides to accompany this call, which you can access through the webcast portal or by going to the Investors page of our website under the Events Presentations section.
Before we begin, I would like to remind you that this call will contain certain forward-looking statements. Specifically, I would like to remind everyone that all statements other than statements of historical facts included in this presentation are forward-looking statements, although we believe that the assumptions made and expectations represented by such statements are reasonable, there can be no assurance that a forward-looking statement contained herein will prove to be accurate.
Given these risks, uncertainties and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
